Trial result ·
A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This trial looked at adults with newly found immune thrombocytopenia, or ITP. People were 18 or older and had not been treated yet. All had low platelet counts at the start. A chance process put each person into one of the groups. 55 people got dexamethasone plus glycyrrhizinate, and 56 got dexamethasone alone. It was a phase 2 trial run at many centres. People and doctors knew which drugs were given.
What they found
The main results used 96 people, with 48 in each group. Each of them got at least one dose. The main goal was a good platelet rise with no bleeding. At month 6, 27 of 48 people on both drugs reached this goal. On dexamethasone alone, 15 of 48 people reached it. The response also lasted longer with both drugs. At day 14, the drug pair did not show this gain. The most common side effects were stomach and gut problems and anxiety. Severe side effects of grade 3-5 did not occur. Nobody died.
What it means for patients
The authors see the drug pair as an improved first treatment for ITP. In this trial, adding glycyrrhizinate led to more platelet responses at month 6. These responses also lasted longer. Severe side effects were not seen in this trial.
Why it is not certain yet
This was a phase 2 trial, an early stage of testing. Only 96 people were in the main results. Some people who joined were left out of these results. Everyone knew which drugs were given, which may sway how results are judged. The gain was not seen at day 14.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia.
PubMed · PMID 42178778We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Immune thrombocytopenia (ITP) publications